文献速递细菌感染、耐药与抗菌药物

IGNITE4:依拉环素对比美罗培南治疗复杂腹腔感染的3期随机双盲试验

IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.
PubMed 文献 · Clin Infect Dis · 2019-01-01

IGNITE4为前瞻性随机双盲多中心3期试验,住院复杂腹腔感染患者接受依拉环素1 mg/kg每12小时或美罗培南1 g每8小时静脉给药4–14天。微生物意向治疗人群治愈访视临床治愈率依拉环素非劣于美罗培南(90.8% vs 91.2%,差值-0.5%,95%CI -6.3至5.3),超过12.5%非劣效界值。

要点

  • 依拉环素1 mg/kg每12小时对复杂腹腔感染的临床治愈率非劣于美罗培南1 g每8小时。
  • 产ESBL肠杆菌感染患者中依拉环素临床治愈率为87.5%(14/16)。
  • 依拉环素恶心、呕吐、腹泻发生率分别低于5%、4%、3%。

核心结论

  • 依拉环素治疗成人复杂腹腔感染在临床治愈率上非劣于美罗培南,包括耐药病原体所致感染。

研究设计与样本

  • IGNITE4为前瞻性、随机、双盲、多中心3期试验(NCT01844856)。
  • 住院复杂腹腔感染患者随机接受依拉环素1 mg/kg每12小时或美罗培南1 g每8小时静脉给药,疗程4–14天。
  • 主要终点为治愈访视(治疗开始后25–31天)微生物意向治疗人群的临床治愈率,非劣效界值12.5%。

主要发现

  • 主要终点临床治愈率:依拉环素177/195(90.8%)vs 美罗培南187/205(91.2%),差值-0.5%,95%CI -6.3至5.3。
  • 改良意向治疗人群临床治愈率:231/250(92.4%)vs 228/249(91.6%),差值0.8,95%CI -4.1至5.8。
  • 临床可评估人群临床治愈率:218/225(96.9%)vs 222/231(96.1%),差值0.8,95%CI -2.9至4.5。
  • 产ESBL肠杆菌患者临床治愈率:依拉环素87.5%(14/16)vs 美罗培南84.6%(11/13)。
  • 依拉环素恶心、呕吐、腹泻发生率分别低于5%、4%、3%。

关键数值与推荐

  • 非劣效界值设为12.5%,主要终点差值-0.5%(95%CI -6.3至5.3)超过该界值。
  • 依拉环素剂量1 mg/kg每12小时,美罗培南1 g每8小时,均为静脉给药,疗程4–14天。
  • 治愈访视时间窗为治疗开始后25–31天。

临床怎么用

  • 对成人复杂腹腔感染,依拉环素可作为美罗培南的替代选择之一。
  • 对产ESBL肠杆菌感染,依拉环素临床治愈率与美罗培南相近。
  • 使用依拉环素时关注恶心、呕吐、腹泻等胃肠道不良反应,本试验中发生率均较低。

局限性

  • 原文摘要未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing antimicrobial resistance among pathogens that cause complicated intraabdominal infections (cIAIs) supports the development of new antimicrobials. Eravacycline, a novel member of the fluorocycline family, is active against multidrug-resistant bacteria including extended-spectrum β-lactamase (ESBL) and carbapenem-resistant Enterobacteriaceae. METHODS: IGNITE4 was a prospective, randomized, double-blind trial. Hospitalized patients with cIAI received either eravacycline 1 mg/kg every 12 hours or meropenem 1 g every 8 hours intravenously for 4-14 days. The primary objective was to demonstrate statistical noninferiority (NI) in clinical cure rates at the test-of-cure visit (25-31 days from start of therapy) in the microbiological intent-to-treat population using a NI margin of 12.5%. Microbiological outcomes and safety were also evaluated. RESULTS: Eravacycline was noninferior to meropenem in the primary endpoint (177/195 [90.8%] vs 187/205 [91.2%]; difference, -0.5%; 95% confidence interval [CI], -6.3 to 5.3), exceeding the prespecified margin. Secondary endpoints included clinical cure rates in the modified ITT population (231/250 [92.4%] vs 228/249 [91.6%]; difference, 0.8; 95% CI, -4.1, 5.8) and the clinically evaluable population (218/225 [96.9%] vs 222/231 [96.1%]; (difference, 0.8; 95% CI -2.9, 4.5). In patients with ESBL-producing Enterobacteriaceae, clinical cure rates were 87.5% (14/16) and 84.6% (11/13) in the eravacycline and meropenem groups, respectively. Eravacycline had relatively low rates of adverse events for a drug of this class, with less than 5%, 4%, and 3% of patients experiencing nausea, vomiting, and diarrhea, respectively. CONCLUSIONS: Treatment with eravacycline was noninferior to meropenem in adult patients with cIAI, including infections caused by resistant pathogens. CLINICAL TRIALS REGISTRATION: NCT01844856.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections. Clin Infect Dis. 2019. PMID: 30561562. doi:10.1093/cid/ciy1029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。